163 related articles for article (PubMed ID: 33554444)
1. GPR39 promotes cardiac hypertrophy by regulating the AMPK-mTOR pathway and protein synthesis.
Liao H; Gao W; Ma J; Xue H; Wang Y; Huang D; Yan F; Ye Y
Cell Biol Int; 2021 Jun; 45(6):1211-1219. PubMed ID: 33554444
[TBL] [Abstract][Full Text] [Related]
2. KLK11 promotes the activation of mTOR and protein synthesis to facilitate cardiac hypertrophy.
Wang Y; Liao H; Wang Y; Zhou J; Wang F; Xie Y; Zhao K; Gao W
BMC Cardiovasc Disord; 2021 May; 21(1):266. PubMed ID: 34059001
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
Liu Y; Li S; Gao Z; Li S; Tan Q; Li Y; Wang D; Wang Q
Cardiovasc Toxicol; 2021 Aug; 21(8):655-668. PubMed ID: 34021461
[TBL] [Abstract][Full Text] [Related]
4. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
Kang S; Chemaly ER; Hajjar RJ; Lebeche D
J Biol Chem; 2011 May; 286(21):18465-73. PubMed ID: 21478152
[TBL] [Abstract][Full Text] [Related]
5. Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling.
Li Y; Zhang D; Kong L; Shi H; Tian X; Gao L; Liu Y; Wu L; Du B; Huang Z; Liang C; Wang Z; Yao R; Zhang Y
Exp Cell Res; 2018 Sep; 370(1):78-86. PubMed ID: 29902536
[TBL] [Abstract][Full Text] [Related]
6. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
Cell Stress Chaperones; 2020 Nov; 25(6):899-908. PubMed ID: 32519137
[TBL] [Abstract][Full Text] [Related]
7. The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling.
Calamaras TD; Lee C; Lan F; Ido Y; Siwik DA; Colucci WS
Free Radic Biol Med; 2015 May; 82():137-46. PubMed ID: 25617592
[TBL] [Abstract][Full Text] [Related]
8. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway.
Li RL; Wu SS; Wu Y; Wang XX; Chen HY; Xin JJ; Li H; Lan J; Xue KY; Li X; Zhuo CL; Cai YY; He JH; Zhang HY; Tang CS; Wang W; Jiang W
J Mol Cell Cardiol; 2018 Aug; 121():242-255. PubMed ID: 30053525
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
Zhou Y; He X; Chen Y; Huang Y; Wu L; He J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):394-9. PubMed ID: 26519882
[TBL] [Abstract][Full Text] [Related]
10. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ
Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430
[TBL] [Abstract][Full Text] [Related]
11. Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
Gao W; Guo N; Zhao S; Chen Z; Zhang W; Yan F; Liao H; Chi K
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32347291
[TBL] [Abstract][Full Text] [Related]
12. Calhex₂₃₁ Ameliorates Cardiac Hypertrophy by Inhibiting Cellular Autophagy in Vivo and in Vitro.
Liu L; Wang C; Sun D; Jiang S; Li H; Zhang W; Zhao Y; Xi Y; Shi S; Lu F; Tian Y; Xu C; Wang L
Cell Physiol Biochem; 2015; 36(4):1597-612. PubMed ID: 26159880
[TBL] [Abstract][Full Text] [Related]
13. Suppression of calcium‑sensing receptor ameliorates cardiac hypertrophy through inhibition of autophagy.
Liu L; Wang C; Lin Y; Xi Y; Li H; Shi S; Li H; Zhang W; Zhao Y; Tian Y; Xu C; Wang L
Mol Med Rep; 2016 Jul; 14(1):111-20. PubMed ID: 27176663
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin attenuates load-induced cardiac hypertrophy in mice.
Shioi T; McMullen JR; Tarnavski O; Converso K; Sherwood MC; Manning WJ; Izumo S
Circulation; 2003 Apr; 107(12):1664-70. PubMed ID: 12668503
[TBL] [Abstract][Full Text] [Related]
15. Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway.
Chen Y; Ge Z; Huang S; Zhou L; Zhai C; Chen Y; Hu Q; Cao W; Weng Y; Li Y
Aging (Albany NY); 2020 Mar; 12(6):5362-5383. PubMed ID: 32209725
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Wang J; Fan S; Xiong Q; Niu Y; Zhang X; Qin J; Shi Y; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2021 Aug; 53(9):1189-1197. PubMed ID: 34357376
[TBL] [Abstract][Full Text] [Related]
17. Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate ameliorates pressure overload-induced cardiac hypertrophy and dysfunction through inhibiting autophagy.
Wang B; Shen D; Tang J; Li J; Xiao Y; Chen X; Cao C; Han D; Gao E; Zhao W; Zhang J; Chang J
J Cell Mol Med; 2019 Sep; 23(9):6048-6059. PubMed ID: 31222939
[TBL] [Abstract][Full Text] [Related]
18. FNDC5/Irisin inhibits pathological cardiac hypertrophy.
Yu Q; Kou W; Xu X; Zhou S; Luan P; Xu X; Li H; Zhuang J; Wang J; Zhao Y; Xu Y; Peng W
Clin Sci (Lond); 2019 Mar; 133(5):611-627. PubMed ID: 30782608
[TBL] [Abstract][Full Text] [Related]
19. Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.
Li XX; Zhang P; Yang Y; Wang JJ; Zheng YJ; Tan JL; Liu SY; Yan YM; Zhang YY; Cheng YX; Yang HT
Acta Pharmacol Sin; 2022 Mar; 43(3):588-601. PubMed ID: 33967278
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy.
Kuzman JA; O'Connell TD; Gerdes AM
Endocrinology; 2007 Jul; 148(7):3477-84. PubMed ID: 17395699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
